Cellectis S.A. (CLLS): Rasio rega marang pendapatan

Simbol lan logo merek Cellectis S.A. (CLLS)

The P/S ratio dynamics of Cellectis S.A. (CLLS) correlate with licensing payments for allogeneic CAR-T cell technology. The business foundation relies on the biotech sector's resilience to crises and the success of clinical phases. Capital secures the alliance with AstraZeneca within the TALEN ecosystem. The value of 2.40 captures this metric, helping to assess the balance between market expectations and the issuer's actual revenue on the chart.

CLLS: Multiplikator P/S Cellectis 04.07.2022 - 13.11.2026

Rincian metrik lan analitis perusahaan Cellectis S.A. (CLLS)

- rega saiki lan proyeksi nilai saham:
Bagan rega cellectis.com|CLLS - Bagan rega target
- data kapitalisasi bursa:
Nilai pasar Cellectis Biotherapeutics|CLLS - Rega Nyata Tumbas Perusahaan Kanthi Wutuh
- statistik nilai buku emiten:
Nilai Akuntansi Saham Cellectis S.A.|CLLS - Kapitalisasi Buku|Rasio Nilai Pasar marang Ekuitas cellectis.com|CLLS - Total Aset Perusahaan
- rincian struktur utang lan likuiditas bisnis:
Utang marang Modal Cellectis S.A.|CLLS - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang modal cellectis.com|CLLS - Gunggung utang perusahaan|Utang-utang marang nilai buku Cellectis Biotherapeutics|CLLS - Kewajiban jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Cellectis S.A.|Rasio likuiditas perantara cellectis.com
- informasi bathi lan kelipatan valuasi:
CLLS - Bathi resik|Penghasilan resik sing dikarepake Cellectis S.A.|CLLS - Pangali P/E|Rasio prakiraan rega marang bathi cellectis.com|CLLS - Rasio rega marang bathi tumrap wutah|Nilai bisnis marang bathi operasional sadurunge panyusutan Cellectis Biotherapeutics|CLLS - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) Cellectis S.A.|CLLS - Bathi saben saham sajrone rolas wulan pungkasan|Dinamika bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan cellectis.com|CLLS - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi resik saben saham ing taun ngarep Cellectis S.A.
- rincian pendapatan lan dodolan emiten:
CLLS - Pendapatan lan volume dodolan|Volume dodolan mangsa ngarep perusahaan cellectis.com|CLLS - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Cellectis Biotherapeutics
Analisis umum perusahaan:CLLS - Cellectis SA
Produk seri Cellectis SA

To minimize risks during long-term investing, it is critical to monitor the proportionality of market capitalization to actual sales volumes, which is reflected in the change of the price-to-sales ratio. Since Cellectis S.A. (CLLS) is in the clinical trial stage and lacks current pricing power, this indicator measures market expectations for the future monetization of its CAR-T patent portfolio rather than current profitability.

Karo sapa Cellectis S.A. saingan

Rasio rega marang pendapatan LEGN (legendbiotech.com)|Rasio rega marang pendapatan Sana Biotechnology, Inc. SANA|Autolus Therapeutics PLC - Rasio rega marang pendapatan|ALLO: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan RNAC (Selecta Biosciences Inc.)|CRBU: Multiplikator P/S|Multiplikator rega marang pendapatan instilbio.com TIL|GNTA (Genenta Science SpA) - Multiplikator P/S|Rega marang dodolan Century Therapeutics Inc IPSC|Rasio rega marang pendapatan Jasper Therapeutics (JSPR)|sentibio.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S ADAP (Adaptimmune Therapeutics)|CERo Therapeutics Holdings, Inc. (CERO) - Rega marang dodolan|TCRT: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan ACHL (Achilles Therapeutics)|CRGX (Cargo Therapeutics) - Kapitalisasi marang pendapatan|PSTX: Kapitalisasi marang volume dodolan|TSVT (2seventy bio, Inc.) - Multiplikator P/S|GRCL: Rasio kapitalisasi pasar marang pendapatan